 |
9 Diseases |  |
0 Trials |
|
0 Trials |  |
68 News |  |
| 12» |
- | Asmanex Twisthaler (mometasone furoate) / Merck (MSD), QVAR (beclomethasone dipropionate hydrofluoroalkane inhalation) / Teva
Journal: Using Filters to Estimate Regional Lung Deposition with Pressurized Metered Dose Inhalers. (Pubmed Central) - Nov 10, 2022
The direct measurement of estimated regional deposition is possible when using the FBA. This method is far less resource intensive than existing methods and so may be useful both for comparison of generic alternatives and the development of innovative products.
- | Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Trial completion, Trial completion date: Stress and Treatment Response in Puerto Rican Children With Asthma (clinicaltrials.gov) - Jul 8, 2022
P=N/A, N=249, Completed, Sponsor: University of Pittsburgh
This method is far less resource intensive than existing methods and so may be useful both for comparison of generic alternatives and the development of innovative products. Recruiting --> Completed | Trial completion date: Dec 2022 --> May 2022
- || Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Trial completion, Combination therapy: Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ? 6 to < 12 Years Old With Asthma (clinicaltrials.gov) - Apr 13, 2022
P2, N=32, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial completion date: Dec 2022 --> May 2022 Recruiting --> Completed
- | Onbrez (indacaterol) / Novartis
Journal: Using Filters to Estimate Regional Lung Deposition with Dry Powder Inhalers. (Pubmed Central) - Feb 4, 2022
Because of its design, the TB filter apparatus makes it possible to estimate regional deposition with inhalers directly using variable inhalation profiles without any additional equipment or changes to the experimental configuration. This method may be useful to expedite development of both innovative and generic drug products as it provides regional respiratory tract deposition estimates using fewer resources than exisiting methods.
- || Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD), Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
PK/PD data, Journal: Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers. (Pubmed Central) - Nov 6, 2021
This method may be useful to expedite development of both innovative and generic drug products as it provides regional respiratory tract deposition estimates using fewer resources than exisiting methods. PK characterization in a healthy volunteer PK study and subsequently an asthma study enabled selection of 80 μg (low), 160 μg (medium), and 320 μg (high) delivered via Breezhaler® as MF doses comparable to the 200 μg, 400 μg and 800 μg doses delivered by Twisthaler®, respectively, as part of QMF149 formulation development.
- || Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Enrollment open, Combination therapy: Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ? 6 to < 12 Years Old With Asthma (clinicaltrials.gov) - Jun 16, 2021
P2, N=32, Recruiting, Sponsor: Novartis Pharmaceuticals
PK characterization in a healthy volunteer PK study and subsequently an asthma study enabled selection of 80 μg (low), 160 μg (medium), and 320 μg (high) delivered via Breezhaler® as MF doses comparable to the 200 μg, 400 μg and 800 μg doses delivered by Twisthaler®, respectively, as part of QMF149 formulation development. Not yet recruiting --> Recruiting
- | Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Trial completion date, Trial primary completion date: Stress and Treatment Response in Puerto Rican Children With Asthma (clinicaltrials.gov) - Apr 23, 2021
P=N/A, N=300, Recruiting, Sponsor: University of Pittsburgh
Not yet recruiting --> Recruiting Trial completion date: Dec 2021 --> Nov 2022 | Trial primary completion date: Oct 2021 --> May 2022
- | Xolair (omalizumab) / Roche, Novartis, Onbrez (indacaterol) / Novartis
Journal: Drugs for asthma. (Pubmed Central) - Jan 26, 2021
Trial completion date: Dec 2021 --> Nov 2022 | Trial primary completion date: Oct 2021 --> May 2022 No abstract available
- | fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Journal: Expanded table: Some inhaled drugs for treatment of asthma. (Pubmed Central) - Jan 26, 2021
No abstract available No abstract available
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Journal: Expanded table: Correct use of inhalers for asthma. (Pubmed Central) - Jan 26, 2021
No abstract available No abstract available
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Journal: Drugs for COPD. (Pubmed Central) - Dec 30, 2020
No abstract available No abstract available
- | Journal: Comparison table: Inhaled corticosteroids for treatment of COPD. (Pubmed Central) - Dec 30, 2020
No abstract available No abstract available
- | Journal: Table: Correct Use of inhalers for COPD. (Pubmed Central) - Dec 30, 2020
No abstract available No abstract available
- || Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
New P2 trial, Combination therapy: Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ? 6 to < 12 Years Old With Asthma (clinicaltrials.gov) - Oct 19, 2020
P2, N=32, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
The struggle. #Asmanex @Merck lol (Twitter) - Jun 30, 2020
- | Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Trial completion date, Trial primary completion date: Stress and Treatment Response in Puerto Rican Children With Asthma (clinicaltrials.gov) - May 20, 2020
P=N/A, N=300, Recruiting, Sponsor: University of Pittsburgh
No abstract available Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Oct 2021
- ||||||| Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Trial completion, Trial primary completion date: PALLADIUM: A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma (clinicaltrials.gov) - Nov 11, 2019
P3, N=2222, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Oct 2021 Recruiting --> Completed | Trial primary completion date: Jul 2019 --> Nov 2018
- |||| Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Trial primary completion date: PALLADIUM: A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma (clinicaltrials.gov) - Mar 14, 2019
P3, N=2000, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Jul 2019 --> Nov 2018 Trial primary completion date: Nov 2018 --> Jul 2019
- | Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Trial initiation date: Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma (clinicaltrials.gov) - Aug 25, 2018
P3, N=750, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2018 --> Jul 2019 Initiation date: May 2010 --> Jan 2017
- | Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Trial completion: SIENA: Steroids In Eosinophil Negative Asthma (clinicaltrials.gov) - Aug 15, 2018
P3, N=295, Completed, Sponsor: Milton S. Hershey Medical Center
Initiation date: May 2010 --> Jan 2017 Active, not recruiting --> Completed
- | Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Enrollment open: Stress and Treatment Response in Puerto Rican Children With Asthma (clinicaltrials.gov) - May 29, 2018
P=N/A, N=300, Recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Phase classification: Stress and Treatment Response in Puerto Rican Children With Asthma (clinicaltrials.gov) - Apr 6, 2018
P, N=300, Not yet recruiting, Sponsor: University of Pittsburgh
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P
- ||||| Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Trial completion date, Trial initiation date, Trial primary completion date: PALLADIUM: A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma (clinicaltrials.gov) - Mar 7, 2018
P3, N=2050, Recruiting, Sponsor: Novartis Pharmaceuticals
Phase classification: P=N/A --> P Trial completion date: Oct 2018 --> Jun 2019 | Initiation date: Dec 2015 --> Dec 2015 | Trial primary completion date: Oct 2018 --> Nov 2018
- | Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Trial initiation date: Stress and Treatment Response in Puerto Rican Children With Asthma (clinicaltrials.gov) - Mar 3, 2018
P=N/A, N=300, Not yet recruiting, Sponsor: University of Pittsburgh
Trial completion date: Oct 2018 --> Jun 2019 | Initiation date: Dec 2015 --> Dec 2015 | Trial primary completion date: Oct 2018 --> Nov 2018 Initiation date: Jan 2018 --> Mar 2018
- ||||||| Dulera (mometasone/formoterol) / Merck (MSD), Novartis, Nasonex (mometasone furoate nasal spray) / Merck (MSD)
Trial completion, Combination therapy: Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087) (clinicaltrials.gov) - Jan 4, 2018
P3, N=182, Completed, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: Jan 2018 --> Mar 2018 Active, not recruiting --> Completed
- | Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Trial initiation date: Stress and Treatment Response in Puerto Rican Children With Asthma (clinicaltrials.gov) - Nov 8, 2017
P=N/A, N=300, Not yet recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Initiation date: Oct 2017 --> Jan 2018
- | Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Enrollment closed, Trial primary completion date: SIENA: Steroids In Eosinophil Negative Asthma (clinicaltrials.gov) - Jul 26, 2017
P3, N=295, Active, not recruiting, Sponsor: Milton S. Hershey Medical Center
Initiation date: Oct 2017 --> Jan 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2017 --> May 2018
- ||||| Dulera (mometasone/formoterol) / Merck (MSD), Novartis, Nasonex (mometasone furoate nasal spray) / Merck (MSD)
Enrollment closed, Combination therapy: Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087) (clinicaltrials.gov) - Jun 26, 2017
P3, N=160, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2017 --> May 2018 Recruiting --> Active, not recruiting
- ||||| Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Trial initiation date: Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma (clinicaltrials.gov) - Jun 15, 2017
P3, N=1000, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Initiation date: Mar 2017 --> May 2010
- | Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
New trial: Stress and Treatment Response in Puerto Rican Children With Asthma (clinicaltrials.gov) - May 1, 2017
P=N/A, N=300, Not yet recruiting, Sponsor: University of Pittsburgh
- |||||| Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Enrollment open: Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma (clinicaltrials.gov) - Apr 6, 2017
P3, N=1000, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2017 --> May 2010 Not yet recruiting --> Recruiting
- |||| Dulera (mometasone/formoterol) / Merck (MSD), Novartis
Trial completion, Monotherapy: SPIRO: A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) (clinicaltrials.gov) - Dec 19, 2016
P4, N=11745, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Trial primary completion date: SIENA: Steroids In Eosinophil Negative Asthma (clinicaltrials.gov) - Sep 14, 2016
P3, N=336, Recruiting, Sponsor: Milton S. Hershey Medical Center
Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Oct 2017
- |||||||||| Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
New P3 trial: Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma (clinicaltrials.gov) - Sep 8, 2016
P3, N=1000, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || Dulera (mometasone/formoterol) / Merck (MSD), Novartis
Trial primary completion date, Monotherapy: SPIRO: A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) (clinicaltrials.gov) - May 25, 2016
P4, N=11664, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Mar 2017 --> Oct 2017 Trial primary completion date: Feb 2017 --> Oct 2016
- |||||| Dulera (mometasone/formoterol) / Merck (MSD), Novartis, Nasonex (mometasone furoate nasal spray) / Merck (MSD)
Enrollment open, Combination therapy: Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087) (clinicaltrials.gov) - May 24, 2016
P3, N=160, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Feb 2017 --> Oct 2016 Not yet recruiting --> Recruiting
- ||| Dulera (mometasone/formoterol) / Merck (MSD), Novartis
Enrollment closed, Monotherapy: SPIRO: A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) (clinicaltrials.gov) - Apr 21, 2016
P4, N=11664, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Dulera (mometasone/formoterol) / Merck (MSD), Novartis, Nasonex (mometasone furoate nasal spray) / Merck (MSD)
New P3 trial, Combination therapy: Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087) (clinicaltrials.gov) - Apr 18, 2016
P3, N=160, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||| Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Enrollment open, Trial primary completion date: PALLADIUM: A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma (clinicaltrials.gov) - Apr 11, 2016
P3, N=2800, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2018 --> Aug 2018
- Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Enrollment closed, Trial primary completion date: Acute and Chronic Effects of Inhaled Steroids on Pulmonary Function in Persons With Spinal Cord Injury (clinicaltrials.gov) - Oct 23, 2015
P1, N=50, Active, not recruiting, Sponsor: James J. Peters Veterans Affairs Medical Center
Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2018 --> Aug 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Mar 2016
- |||||||||| Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
New P3 trial: PALLADIUM: A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma (clinicaltrials.gov) - Sep 18, 2015
P3, N=2800, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Trial primary completion date: SIENA: Steroids In Eosinophil Negative Asthma (clinicaltrials.gov) - Apr 15, 2015
P3, N=384, Recruiting, Sponsor: Milton S. Hershey Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Mar 2016 Trial primary completion date: Sep 2016 --> Mar 2017
- Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Enrollment open, Enrollment change, Trial primary completion date: Acute and Chronic Effects of Inhaled Steroids on Pulmonary Function in Persons With Spinal Cord Injury (clinicaltrials.gov) - Mar 31, 2015
P1, N=50, Recruiting, Sponsor: James J. Peters Veterans Affairs Medical Center
Trial primary completion date: Sep 2016 --> Mar 2017 Not yet recruiting --> Recruiting | N=15 --> 50 | Trial primary completion date: Aug 2013 --> Mar 2015
- |||| Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Trial completion: A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223) (clinicaltrials.gov) - Feb 6, 2015
P2, N=583, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting | N=15 --> 50 | Trial primary completion date: Aug 2013 --> Mar 2015 Active, not recruiting --> Completed
- ||||| Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Trial initiation date: A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880) (clinicaltrials.gov) - Dec 9, 2014
P3, N=180, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Initiation date: Nov 2006 --> Jun 2007
- | Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Trial completion, Trial primary completion date: Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=22, Completed, Sponsor: University of Miami
Initiation date: Nov 2006 --> Jun 2007 Not yet recruiting --> Completed | Trial primary completion date: Oct 2012 --> Feb 2013
- ||| Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Enrollment closed: A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223) (clinicaltrials.gov) - Nov 11, 2014
P2, N=600, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Completed | Trial primary completion date: Oct 2012 --> Feb 2013 Recruiting --> Active, not recruiting
- | Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
Enrollment open, Trial primary completion date: SIENA: Steroids In Eosinophil Negative Asthma (clinicaltrials.gov) - Jul 12, 2014
P3, N=384, Recruiting, Sponsor: Milton S. Hershey Medical Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2016 --> Sep 2016
- || Asmanex Twisthaler (mometasone furoate) / Merck (MSD)
New P3 trial: SIENA: Steroids In Eosinophil Negative Asthma (clinicaltrials.gov) - Feb 17, 2014
P3, N=384, Not yet recruiting, Sponsor: Milton S. Hershey Medical Center
- |||| Dulera (mometasone/formoterol) / Merck (MSD), Novartis
Enrollment open, Monotherapy: SPIRO: A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) (clinicaltrials.gov) - Mar 21, 2012
P4, N=11664, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2016 --> Sep 2016 Not yet recruiting --> Recruiting